Publications

Publications in 2022

  • Cummings JL, Devanand DP, Stahl SM. Dementia-related psychosis and the potential role for pimavanserin. Vol. 27, CNS Spectrums. Cambridge University Press; 2022. p. 7–15.

Publications in 2021

  • Abate G, Vezzoli M, Polito L, Guaita A, Albani D, Marizzoni M, et al. A conformation variant of p53 combined with machine learning identifies alzheimer disease in preclinical and prodromal stages. J Pers Med. 2021 Jan 1;11(1):1–16.
  • Armstrong MJ, Sullivan JL, Amodeo K, Lunde A, Tsuang DW, Reger MA, et al. Suicide and Lewy body dementia: Report of a Lewy body dementia association working group. Vol. 36, International Journal of Geriatric Psychiatry. John Wiley and Sons Ltd; 2021. p. 373–82.
  • Caldwell JZK, Kinney JW, Ritter A, Salazar A, Wong CG, Cordes D, et al. Inflammatory cytokine levels implicated in Alzheimer’s disease moderate the effects of sex on verbal memory performance. Brain Behav Immun. 2021 Jul 1;95:27–35.
  • Cummings J. The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative Diseases. Vol. 29, American Journal of Geriatric Psychiatry. Elsevier B.V.; 2021. p. 375–83.
  • Cummings J. Drug development for psychotropic, cognitive-enhancing, and disease-modifying treatments for alzheimer’s disease. J Neuropsychiatry Clin Neurosci. 2021 Jan 1;33(1):3–13.
  • Cummings J. New approaches to symptomatic treatments for Alzheimer’s disease. Vol. 16, Molecular Neurodegeneration. BioMed Central Ltd; 2021.
  • Hellton KH, Cummings J, Vik-Mo AO, Nordrehaug JE, Aarsland D, Selbaek G, et al. The Truth behind the Zeros: A New Approach to Principal Component Analysis of the Neuropsychiatric Inventory. Multivariate Behav Res. 2021;56(1):70–85.
  • Matthews DC, Ritter A, Thomas RG, Andrews RD, Lukic AS, Revta C, et al. Rasagiline effects on glucose metabolism, cognition, and tau in Alzheimer’s dementia. Alzheimer’s Dement Transl Res Clin Interv. 2021;7(1).
  • Richardson S, Sinha A, Vahia I, Dawson W, Kaye J, Reynolds CF, et al. Brain Health Living Labs. Am J Geriatr Psychiatry. 2021 Jul 1;29(7):698–703.
  • Sabbagh MN, Pope E, Cordes L, Shi J, DeCourt B. Therapeutic considerations for APOE and TOMM40 in Alzheimers disease: A tribute to Allen Roses MD. Expert Opin Investig Drugs. 2021;30(1):39–44.
  • Salazar AM, Leisgang AM, Ortiz AA, Murtishaw AS, Kinney JW. Alterations of GABA B receptors in the APP/PS1 mouse model of Alzheimer’s disease. Neurobiol Aging. 2021
  • Smith E, Ali D, Wilkerson B, Dawson WD, Sobowale K, Reynolds C, et al. A Brain Capital Grand Strategy: toward economic reimagination. Vol. 26, Molecular Psychiatry. Springer Nature; 2021. p. 3–22.

Publications in 2020

  • Aisen PS, Cummings J, Doody R, Kramer L, Salloway S, Selkoe DJ, et al. The Future of Anti-Amyloid Trials. J Prev Alzheimer’s Dis. 2020 Mar 1;7(3):146–51.

  • Aisen PS, Sperling RA, Cummings J, Donohue MC, Langford O, Jimenez-Maggiora GA, et al. The Trial-Ready Cohort for Preclinical/Prodromal Alzheimer’s Disease (TRC-PAD) Project: An Overview. J Prev Alzheimer’s Dis. 2020 Aug 1;7(4):208–12.

  • Ballard C, Aarsland D, Cummings J, O’Brien J, Mills R, Molinuevo JL, et al. Drug repositioning and repurposing for Alzheimer disease. Vol. 16, Nature Reviews Neurology. Nature Research; 2020. p. 661–73.

  • Bauzon J, Lee G, Cummings J. Repurposed agents in the Alzheimer’s disease drug development pipeline. Alzheimer’s Res Ther. 2020 Aug 17;12(1).

  • Bayram E, Banks SJ, Shan G, Kaplan N, Caldwell JZK. Sex Differences in Cognitive Changes in de Novo Parkinson’s Disease. J Int Neuropsychol Soc. 2020 Feb 1;26(2):241–9.

  • Beach TG, Adler CH, Zhang N, Serrano GE, Sue LI, Driver-Dunckley E, et al. Severe hyposmia distinguishes neuropathologically confirmed dementia with Lewy bodies from Alzheimer’s disease dementia. PLoS One. 2020 Apr 1;15(4).

  • Bennett LL, Stephen SJ, Bernick C, Shan G, Banks SJ. Sex Moderates the Relationship That Number of Professional Fights Has With Cognition and Brain Volumes. Front Neurol. 2020 Oct 29;11.

  • Bernick C, Shan G, Zetterberg H, Banks S, Mishra VR, Bekris L, et al. Longitudinal change in regional brain volumes with exposure to repetitive head impacts. Neurology. 2020 Jan 21;94(3):e232–40.

  • Cummings J. The Neuropsychiatric Inventory: Development and Applications. Vol. 33, Journal of Geriatric Psychiatry and Neurology. SAGE Publications Inc.; 2020. p. 73–84.

  • Cummings J. The Role of Clinical Trials in Preclinical Alzheimer’s Disease Drug Development Programs. J Prev Alzheimer’s Dis. 2020 Aug 1;7(4):288–90.

  • Cummings JL. Translational Scoring of Candidate Treatments for Alzheimer’s Disease: A Systematic Approach. Dement Geriatr Cogn Disord. 2020 Sep 1;49(1):22–37.

  • Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2020. Alzheimer’s Dement Transl Res Clin Interv. 2020;6(1).

  • Cummings J, Pinto LC, Cruz M, Fischer CE, Gerritsen DL, Grossberg GT, et al. Criteria for Psychosis in Major and Mild Neurocognitive Disorders: International Psychogeriatric Association (IPA) Consensus Clinical and Research Definition. Vol. 28, American Journal of Geriatric Psychiatry. Elsevier B.V.; 2020. p. 1256–69.

  • Dawson WD, Bobrow K, Ibanez A, Booi L, Pintado-Caipa M, Yamamoto S, et al. The necessity of diplomacy in brain health. Vol. 19, The Lancet Neurology. Lancet Publishing Group; 2020. p. 972–4.

  • Decourt B, Wilson J, Ritter A, Dardis C, Difilippo FP, Zhuang X, et al. MCLENA-1: A phase ii clinical trial for the assessment of safety, tolerability, and efficacy of lenalidomide in patients with mild cognitive impairment due to alzheimer’s disease. Open Access J Clin Trials. 2020;12:1–13.

  • Digma LA, Madsen JR, Rissman RA, Jacobs DM, Brewer JB, Banks SJ. Women can bear a bigger burden: ante- and post-mortem evidence for reserve in the face of tau. Brain Commun. 2020;2(1).

  • Fang J, Pieper AA, Nussinov R, Lee G, Bekris L, Leverenz JB, et al. Harnessing endophenotypes and network medicine for Alzheimer’s drug repurposing. Vol. 40, Medicinal Research Reviews. John Wiley and Sons Inc; 2020. p. 2386–426.

  • Fischer CE, Ismail Z, Youakim JM, Creese B, Kumar S, Nuñez N, et al. Revisiting Criteria for Psychosis in Alzheimer’s Disease and Related Dementias: Toward Better Phenotypic Classification and Biomarker Research. J Alzheimers Dis. 2020;73(3):1143–56.

  • Gauthier S, Aisen PS, Cummings J, Detke MJ, Longo FM, Raman R, et al. Non-Amyloid Approaches to Disease Modification for Alzheimer’s Disease: An EU/US CTAD Task Force Report. J Prev Alzheimer’s Dis. 2020 Mar 1;7(3):152–7.

  • Grossberg GT, Kohegyi E, Mergel V, Josiassen MK, Meulien D, Hobart M, et al. Efficacy and Safety of Brexpiprazole for the Treatment of Agitation in Alzheimer’s Dementia: Two 12-Week, Randomized, Double-Blind, Placebo-Controlled Trials. Am J Geriatr Psychiatry. 2020 Apr 1;28(4):383–400.

  • Hannestad J, Koborsi K, Klutzaritz V, Chao W, Ray R, Páez A, et al. Safety and tolerability of GRF6019 in mild-to-moderate Alzheimer’s disease dementia. Alzheimer’s Dement Transl Res Clin Interv. 2020;6(1).

  • Henderson ST, Morimoto BH, Cummings JL, Farlow MR, Walker J. A Placebo-Controlled, Parallel-Group, Randomized Clinical Trial of AC-1204 in Mild-to-Moderate Alzheimer’s Disease. J Alzheimer’s Dis. 2020 May 19;75(2):547–57.

  • Hjetland GJ, Nordhus IH, Pallesen S, Cummings J, Tractenberg RE, Thun E, et al. An Actigraphy-Based Validation Study of the Sleep Disorder Inventory in the Nursing Home. Front Psychiatry. 2020 Mar 13;11.

  • Jiang T, Cao B, Shan G. Accurate confidence intervals for risk difference in meta-analysis with rare events. BMC Med Res Methodol. 2020 Apr 30;20(1).

  • Jimenez-Maggiora GA, Bruschi S, Raman R, Langford O, Donohue M, Rafii MS, et al. TRC-PAD: Accelerating Recruitment of AD Clinical Trials through Innovative Information Technology. J Prev Alzheimer’s Dis. 2020 Aug 1;7(4):226–33.

  • Langford O, Raman R, Sperling RA, Cummings J, Sun CK, Jimenez-Maggiora G, et al. Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials. J Prev Alzheimer’s Dis. 2020 Aug 1;7(4):213–8.

  • Sabbagh M, Sadowsky C, Tousi B, Agronin ME, Alva G, Armon C, et al. Effects of a combined transcranial magnetic stimulation (TMS) and cognitive training intervention in patients with Alzheimer’s disease. Alzheimer’s Dement. 2020 Apr 1;16(4):641–50.

  • Shan G, Bayram E, Caldwell JZK, Miller JB, Shen JJ, Gerstenberger S. Partial Correlation Coefficient for a Study With Repeated Measurements. Stat Biopharm Res. 2020 Jul 20;13(4):448–54.

  • Shan G, Zhang H, Jiang T. Correlation Coefficients for a Study with Repeated Measures. Comput Math Methods Med. 2020;2020.

  • Stephen SJ, Shan G, Banks SJ, Bernick C, Bennett LL. The Relationship Between Fighting Style, Cognition, and Regional Brain Volume in Professional Combatants: A Preliminary Examination Using Brief Neurocognitive Measures. J Head Trauma Rehabil. 2020 May 1;35(3):E280–7.

  • Sur C, Kost J, Scott D, Adamczuk K, Fox NC, Cummings JL, et al. BACE inhibition causes rapid, regional, and non-progressive volume reduction in Alzheimer’s disease brain. Brain. 2020 Dec 1;143(12):3816–26.

  • Ternes K, Iyengar V, Lavretsky H, Dawson WD, Booi L, Ibanez A, et al. Brain health INnovation Diplomacy: A model binding diverse disciplines to manage the promise and perils of technological innovation. Vol. 32, International Psychogeriatrics. Cambridge University Press; 2020. p. 955–79.

  • Tolar M, Abushakra S, Sabbagh M. The path forward in Alzheimer’s disease therapeutics: Reevaluating the amyloid cascade hypothesis. Alzheimer’s Dement. 2020 Nov 1;16(11):1553–60.

  • Walter S, Clanton TB, Langford OG, Rafii MS, Shaffer EJ, Grill JD, et al. Recruitment into the Alzheimer Prevention Trials (APT) Webstudy for a Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD). J Prev Alzheimer’s Dis. 2020 Aug 1;7(4):219–25.

  • Walter S, Langford OG, Clanton TB, Jimenez-Maggiora GA, Raman R, Rafii MS, et al. The Trial-Ready Cohort for Preclinical and Prodromal Alzheimer’s Disease (TRC-PAD): Experience from the First 3 Years. J Prev Alzheimer’s Dis. 2020 Aug 1;7(4):234–41.

  • Wessels AM, Lines C, Stern RA, Kost J, Voss T, Mozley LH, et al. Cognitive outcomes in trials of two BACE inhibitors in Alzheimer’s disease. Alzheimer’s Dement. 2020 Nov 1;16(11):1483–92.

  • Yang Z, Zhuang X, Sreenivasan K, Mishra V, Curran T, Cordes D. A robust deep neural network for denoising task-based fMRI data: An application to working memory and episodic memory. Med Image Anal. 2020 Feb 1;60.

Publications in 2019

  • Adler CH, Beach TG, Zhang N, Shill HA, Driver-Dunckley E, Caviness JN, et al. Unified staging system for Lewy body disorders: Clinicopathologic correlations and comparison to Braak staging. J Neuropathol Exp Neurol. 2019 Oct 1;78(10):891–9.
  • Ballard C, Atri A, Boneva N, Cummings JL, Frölich L, Molinuevo JL, et al. Enrichment factors for clinical trials in mild-to-moderate Alzheimer’s disease. Alzheimer’s Dement Transl Res Clin Interv. 2019 Jan 1;5:164–74.
  • Banks SJ, Bayram E, Shan G, LaBelle DR, Bluett B. Non-motor predictors of freezing of gait in Parkinson’s disease. Gait Posture. 2019 Feb 1;68:311–6.
  • Banks SJ, Shifflett B, Berg JL, Sundermann E, Peavy G, Bondi MW, et al. Sex-specific composite scales for longitudinal studies of incipient Alzheimer’s disease. Alzheimer’s Dement Transl Res Clin Interv. 2019 Jan 1;5:508–14.
  • Bayram E, Bluett B, Zhuang X, Cordes D, LaBelle DR, Banks SJ. Neural correlates of distinct cognitive phenotypes in early Parkinson’s disease. J Neurol Sci. 2019 Apr 15;399:22–9.
  • Bayram E, Kaplan N, Shan G, Caldwell JZK. The longitudinal associations between cognition, mood and striatal dopaminergic binding in Parkinson’s Disease. Aging, Neuropsychol Cogn. 2019 Aug 14;27(4):581–94.
  • Bayram E, Shan G, Cummings JL. Associations between comorbid TDP-43, Lewy body pathology, and neuropsychiatric symptoms in Alzheimer’s disease. J Alzheimer’s Dis. 2019;69(4):953–61.
  • Bennett LL, Arias JJ, Ford PJ, Bernick C, Banks SJ. Concussion reporting and perceived knowledge of professional fighters. Phys Sportsmed. 2019 Jul 3;47(3):295–300.
  • Bernard K, Gouttefangeas S, Bretin S, Galtier S, Robert P, Holthoff-Detto V, et al. A 24-week double-blind placebo-controlled study of the efficacy and safety of the AMPA modulator S47445 in patients with mild to moderate Alzheimer’s disease and depressive symptoms. Alzheimer’s Dement Transl Res Clin Interv. 2019 Jan 1;5:231–40.
  • Brunet HE. P, Cummings JL. MS, Banks SJ. P, Miller JP. Awareness of Psychiatric Symptoms in a Mixed Clinical Sample of Older Adults. Aware Psychiatr Symptoms a Mix Clin Sample Older Adults. 2019 Aug 11;33(3).
  • Brunet HE, Caldwell JZK, Brandt J, Miller JB. Influence of sex differences in interpreting learning and memory within a clinical sample of older adults. Aging, Neuropsychol Cogn. 2019 Jan 20;27(1):18–39.
  • Brunet HE, Miller JB, Shi J, Chung B, Munter BT, Sabbagh MN. Does informant-based reporting of cognitive symptoms predict amyloid positivity on positron emission tomography? Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2019 Dec 1;11:424–9.
  • Caldwell JZK, Cummings JL, Banks SJ, Palmqvist S, Hansson O. Cognitively normal women with Alzheimer’s disease proteinopathy show relative preservation of memory but not of hippocampal volume. Alzheimer’s Res Ther. 2019 Dec 26;11(1).
  • Caldwell JZK, Zhuang X, Leavitt MJ, Banks SJ, Cummings J, Cordes D. Sex moderates amyloid and apolipoprotein ε4 effects on default mode network connectivity at rest. Front Neurol. 2019;10(AUG).
  • Chiu MJ, Lue LF, Sabbagh MN, Chen TF, Chen HH, Yang SY. Long-Term Storage Effects on Stability of Aβ1-40, Aβ1-42, and Total Tau Proteins in Human Plasma Samples Measured with Immunomagnetic Reduction Assays. Dement Geriatr Cogn Dis Extra. 2019 Jan 1;9(1):77–86.
  • Cummings J. The National Institute on Aging—Alzheimer’s Association Framework on Alzheimer’s disease: Application to clinical trials. Vol. 15, Alzheimer’s and Dementia. Elsevier Inc.; 2019. p. 172–8.
  • Cummings JL, Tong G, Ballard C. Treatment Combinations for Alzheimer’s Disease: Current and Future Pharmacotherapy Options. Vol. 67, Journal of Alzheimer’s Disease. IOS Press; 2019. p. 779–94.
  • Cummings J, Blennow K, Johnson K, Keeley M., Bateman RJ, Molinuevo JL, et al. Anti-Tau Trials for Alzheimer’s Disease: A Report from the EU/US/CTAD Task Force. J Prev Alzheimer’s Dis. 2019 Apr 18;6:157–63.
  • Cummings J, Feldman HH, Scheltens P. The “rights” of precision drug development for Alzheimer’s disease. Vol. 11, Alzheimer’s Research and Therapy. BioMed Central Ltd.; 2019.
  • Cummings J, Lee G, Ritter A, Sabbagh M, Zhong K. Alzheimer’s disease drug development pipeline: 2019. Alzheimer’s Dement Transl Res Clin Interv. 2019 Jan 1;5:272–93.
  • Cummings J, Passmore P, McGuinness B, Mok V, Chen C, Engelborghs S, et al. Souvenaid in the management of mild cognitive impairment: An expert consensus opinion. Vol. 11, Alzheimer’s Research and Therapy. BioMed Central Ltd.; 2019.
  • Cummings J, Ritter A, Rothenberg K. Advances in Management of Neuropsychiatric Syndromes in Neurodegenerative Diseases. Vol. 21, Current Psychiatry Reports. Current Medicine Group LLC 1; 2019.
  • Digma LA, Madsen JR, Reas ET, Dale AM, Brewer JB, Banks SJ. Tau and atrophy: Domain-specific relationships with cognition. Alzheimer’s Res Ther. 2019 Jul 27;11(1).
  • Dugger BN, Hoffman BR, Scroggins A, Serrano GE, Adler CH, Shill HA, et al. Tau immunoreactivity in peripheral tissues of human aging and select tauopathies. Neurosci Lett. 2019 Mar 23;696:132–9.
  • Durant J, Berg J-L, Banks SJ, Kaylegian J, Miller JB. Comparing the Boston Naming Test With the Neuropsychological Assessment Battery–Naming Subtest in a Neurodegenerative Disease Clinic Population. Assessment. 2019 Sep 13;28(5).
  • Durant J, Duff K, Miller JB. Regression-based formulas for predicting change in memory test scores in healthy older adults: Comparing use of raw versus standardized scores. J Clin Exp Neuropsychol. 2019 Feb 5;41(5):460–8.
  • Egan MF, Kost J, Voss T, Mukai Y, Aisen PS, Cummings JL, et al. Randomized Trial of Verubecestat for Prodromal Alzheimer’s Disease. N Engl J Med. 2019 Apr 11;380(15):1408–20.
  • Egan MF, Mukai Y, Voss T, Kost J, Stone J, Furtek C, et al. Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer’s disease. Alzheimer’s Res Ther. 2019 Aug 7;11(1).
  • El-Nazer R, Adler CH, Beach TG, Belden Christine M., Artz J, Shill HA, et al. Regional neuropathology distribution and verbal fluency impairments in Parkinson’s disease. Park Relat Disord. 2019 Aug;65:73–8.
  • Feng L, Li H, Oishi K, Mishra V, Song L, Peng Q, et al. Age-specific gray and white matter DTI atlas for human brain at 33, 36 and 39 postmenstrual weeks. Neuroimage. 2019 Jan 15;185:685–98.
  • Fitzhugh MC, Braden BB, Sabbagh MN, Rogalsky C, Baxter LC. Age-Related Atrophy and Compensatory Neural Networks in Reading Comprehension. J Int Neuropsychol Soc. 2019 Apr 29;25(6):569–82.
  • Frölich L, Atri A, Ballard C, Tariot PN, Molinuevo JL, Boneva N, et al. Open-Label, Multicenter, Phase III Extension Study of Idalopirdine as Adjunctive to Donepezil for the Treatment of Mild-Moderate Alzheimer’s Disease. J Alzheimer’s Dis. 2019 Jan 8;67(1):303–13.
  • Gauthier S, Alam J, Fillit H, Iwatsubo T, Liu-Seifert H, Sabbagh M, et al. Combination Therapy for Alzheimer’s Disease: Perspectives of the EU/US CTAD Task Force. J Prev Alzheimer’s Dis. 2019 Apr 18;6:164–8.
  • Goud KY, Moonla C, Mishra RK, Yu C, Narayan R, Litvan I, et al. Wearable Electrochemical Microneedle Sensor for Continuous Monitoring of Levodopa: Toward Parkinson Management. ACS Sensors. 2019;4(8):2196–204.
  • Hoskin JL, Sabbagh MN, Al-Hasan Y, Decourt B. Tau immunotherapies for Alzheimer’s disease. Expert Opin Investig Drugs. 2019 Jun 3;28(6):545–54.
  • Jalene S, Pharr J, Shan G, Poston B. Estimated Cardiorespiratory Fitness Is Associated With Reported Depression in College Students. Front Physiol. 2019 Sep 18;10.
  • Jones SE, Idris A, Bullen JA, Miller JB, Banks SJ. Relationship between cortical thickness and fluency in the memory disorders clinic population. Neuropsychologia. 2019 Jun 1;129:294–301.
  • Landers MR, Johnson KN, Johnson S, Ormsby T, Salgo DC, Zorn JB, et al. Pre-diagnosis physical activity habits are associated with age of diagnosis in Parkinson’s disease. Clin Park Relat Disord. 2019 Jan 1;1:25–30.
  • Landers MR, Navalta JW, Murtishaw AS, Kinney JW, Pirio Richardson S. A High-Intensity Exercise Boot Camp for Persons with Parkinson Disease: A Phase II, Pragmatic, Randomized Clinical Trial of Feasibility, Safety, Signal of Efficacy, and Disease Mechanisms. J Neurol Phys Ther. 2019 Jan 1;43(1):12–25.
  • Lee B, Bennett LL, Bernick C, Shan G, Banks SJ. The Relations among Depression, Cognition, and Brain Volume in Professional Boxers: A Preliminary Examination Using Brief Clinical Measures. J Head Trauma Rehabil. 2019 Nov 1;34(6):E29–39.
  • Lee G, Cummings J, Decourt B, Leverenz JB, Sabbagh MN. Clinical drug development for dementia with Lewy bodies: past and present. Vol. 28, Expert Opinion on Investigational Drugs. Taylor and Francis Ltd; 2019. p. 951–65.
  • Lue Yu-Min Kuo Marwan Sabbagh L-F, Lue L, Kuo Y, Sabbagh M. Advance in Plasma AD Core Biomarker Development: Current Findings from Immunomagnetic Reduction-Based SQUID Technology. Neurol Ther [Internet]. 2019;8:95–111. Available from: https://doi.org/10.6084/
  • Lue LF, Pai MC, Chen TF, Hu CJ, Huang LK, Lin WC, et al. Age-Dependent Relationship Between Plasma Aβ40 and Aβ42 and Total Tau Levels in Cognitively Normal Subjects. Front Aging Neurosci. 2019 Sep 3;11.
  • Mark DK, John Z, Marwan QW, Sabbagh N. Polypharmacy in an Elderly Population: Enhancing Medication Management Through the Use of Clinical Decision Support Software Platforms. Neurol Ther [Internet]. 2019;8:79–94. Available from: https://doi.org/10.6084/
  • Mazurenko O, Shen J, Shan G, Greenway J. Nevada’s Medicaid Expansion and Admissions for Ambulatory Care-Sensitive Conditions. Am J Manag Care [Internet]. 2019 [cited 2022 Nov 3];24(5):157–63. Available from: https://hdl.handle.net/1805/21257
  • McCrudden MT, Marchand G, Schutz P. Mixed methods in educational psychology inquiry. Vol. 57, Contemporary Educational Psychology. Academic Press Inc.; 2019. p. 1–8.
  • Mishra VR, Sreenivasan KR, Zhengshi Yang, Zhuang X, Cordes D, Mari Z, et al. Unique white matter structural connectivity in early-stage drug-naive Parkinson disease. Neurology. 2019 Feb 25;94(8).
  • Mishra VR, Sreenivasan KR, Zhuang X, Yang Z, Cordes D, Banks SJ, et al. Understanding white matter structural connectivity differences between cognitively impaired and nonimpaired active professional fighters. Hum Brain Mapp. 2019 Dec 1;40(17):5108–22.
  • Mishra VR, Sreenivasan KR, Zhuang X, Yang Z, Cordes D, Walsh RR. Influence of analytic techniques on comparing DTI-derived measurements in early stage Parkinson’s disease. Heliyon [Internet]. 2019; Available from: https://doi.org/10.1016/j.heliyon.2019.e01481
  • Nance C, Ritter A, Miller JB, Lapin B, Banks SJ. The Pathology of Rapid Cognitive Decline in Clinically Diagnosed Alzheimer’s Disease. J Alzheimer’s Dis. 2019;70(4):982–93.
  • Ouyang M, Jeon T, Sotiras A, Peng Q, Mishra V, Halovanic C, et al. Differential cortical microstructural maturation in the preterm human brain with diffusion kurtosis and tensor imaging. Proc Natl Acad Sci U S A. 2019;116(10):4681–8.
  • Ray KK, Nicholls SJ, Ginsberg HD, Johansson JO, Kalantar-Zadeh K, Kulikowski E, et al. Effect of selective BET protein inhibitor apabetalone on cardiovascular outcomes in patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE trial. Am Heart J. 2019 Nov 1;217:72–83.
  • Sabbagh MN, Hendrix S, Harrison JE. FDA position statement “Early Alzheimer’s disease: Developing drugs for treatment, Guidance for Industry.” Vol. 5, Alzheimer’s and Dementia: Translational Research and Clinical Interventions. Elsevier Inc; 2019. p. 13–9.
  • Shan G, Hutson A, Wilding GE, Ma C, Tian G-L. Efficient statistical inference for a parallel study with missing data by using an exact method. J Biopharm Stat. 2019 Apr 29;29(3):478–90.
  • Shan G, Zhang H. Two-stage optimal designs with survival endpoint when the follow-up time is restricted. BMC Med Res Methodol. 2019 Apr 3;19(1).
  • Shan G, Zhang H, Jiang T. Adaptive two-stage optimal designs for phase II clinical studies that allow early futility stopping. Seq Anal. 2019 Jul 19;38(2):199–213.
  • Shen JJ, Shan G, Kim PC, Yoo JW, Dodge-Francis C, Lee YJ. Trends and Related Factors of Cannabis-Associated Emergency Department Visits in the United States: 2006-2014. J Addict Med. 2019 May 1;13(3):193–200.
  • Song M, Lieberman A, Fife T, Nielsen M, Hayden S, Sabbagh M, et al. A prospective study on gait dominant normal pressure hydrocephalus. Acta Neurol Scand. 2019 Apr 1;139(4):389–94.
  • Sorenson K, Sabbagh MN, Johnson M, Azuma T. Do Neuropsychological Profiles Differ between Amyloid PET Positive and Negative Amnestic MCI Subjects? J Alzheimers Dis Park. 2019 Aug 30;9(5).
  • Sreenivasan K, Mishra V, Bird C, Zhuang X, Yang Z, Cordes D, et al. Altered functional network topology correlates with clinical measures in very early-stage, drug-naïve Parkinson’s disease. Park Relat Disord. 2019 May 1;62:3–9.
  • Yang Z, Zhuang X, Bird C, Sreenivasan K, Mishra V, Banks S, et al. Performing sparse regularization and dimension reduction simultaneously in multimodal data fusion. Front Neurosci. 2019;13(JUL).
  • Yang Z, Zhuang X, Sreenivasan K, Mishra V, Cordes D. Robust Motion Regression of Resting-State Data Using a Convolutional Neural Network Model. Front Neurosci [Internet]. 2019 Feb 28;13. Available from: https://www.frontiersin.org/article/10.3389/fnins.2019.00169/full
  • Zhang H, Song Y, Jiang B, Chen B, Shan G. Two-Stage Bagging Pruning for Reducing the Ensemble Size and Improving the Classification Performance. Math Probl Eng. 2019;2019.
  • Zhao T, Mishra V, Jeon T, Ouyang M, Peng Q, Chalak L, et al. Structural network maturation of the preterm human brain. Neuroimage. 2019 Jan 15;185:699–710.
  • Zhuang X, Yang Z, Sreenivasan KR, Mishra VR, Curran T, Nandy R, et al. Multivariate group-level analysis for task fMRI data with canonical correlation analysis. Neuroimage. 2019 Jul 1;194:25–41.

Publications in 2018

  • Aslam S, Fritz MA, Cordes L, Sabbagh MN. What Promises the CJD Diagnosis in a Case of Rapidly Progressive Dementia? J Alzheimer’s Dis Park. 2018;08(05).

  • Atri A, Frölich L, Ballard C, Tariot PN, Molinuevo JL, Boneva N, et al. Effect of idalopirdine as adjunct to cholinesterase inhibitors on change in cognition in patients with Alzheimer disease three randomized clinical trials. In: JAMA – Journal of the American Medical Association. American Medical Association; 2018. p. 130–42.

  • Baer M, Klemetson B, Scott D, Murtishaw AS, Navalta JW, Kinney JW, et al. Effects of Fatigue on Balance in Individuals with Parkinson Disease: Influence of Medication and Brain-Derived Neurotrophic Factor Genotype. In: Journal of Neurologic Physical Therapy. Lippincott Williams and Wilkins; 2018. p. 61–71.

  • Ballard C, Banister C, Khan Z, Cummings J, Demos G, Coate B, et al. Evaluation of the safety, tolerability, and efficacy of pimavanserin versus placebo in patients with Alzheimer’s disease psychosis: a phase 2, randomised, placebo-controlled, double-blind study [Internet]. Vol. 17, Articles Lancet Neurology. 2018. Available from: www.thelancet.com/neurology

  • Banks SJ, Zhuang X, Bayram E, Bird C, Cordes D, Caldwell JZK, et al. Default Mode Network Lateralization and Memory in Healthy Aging and Alzheimer’s Disease. J Alzheimer’s Dis. 2018;66(3):1223–34.

  • Bayram E, Caldwell JZK, Banks SJ. Current understanding of magnetic resonance imaging biomarkers and memory in Alzheimer’s disease. Vol. 4, Alzheimer’s and Dementia: Translational Research and Clinical Interventions. Elsevier Inc; 2018. p. 395–413.

  • Berg JL, Durant J, Léger GC, Cummings JL, Nasreddine Z, Miller JB. Comparing the Electronic and Standard Versions of the Montreal Cognitive Assessment in an Outpatient Memory Disorders Clinic: A Validation Study. J Alzheimer’s Dis. 2018;62(1):93–7.

  • Bernick C, Zetterberg H, Shan G, Banks S, Blennow K. Longitudinal Performance of Plasma Neurofilament Light and Tau in Professional Fighters: The Professional Fighters Brain Health Study. J Neurotrauma. 2018 Oct 1;35(20):2351–6.

  • Bluett B, Banks S, Cordes D, Bayram E, Mishra V, Cummings J, et al. Neuroimaging and neuropsychological assessment of freezing of gait in Parkinson’s disease. Alzheimer’s Dement Transl Res Clin Interv. 2018 Jan 1;4:387–94.

  • Caldwell JZK, Berg JL, Shan G, Cummings JL, Banks SJ. Sex Moderates the Impact of Diagnosis and Amyloid PET Positivity on Hippocampal Subfield Volume. J Alzheimer’s Dis. 2018;64(1):79–89.

  • Cordes D, Zhuang X, Kaleem M, Sreenivasan K, Yang Z, Mishra V, et al. Advances in functional magnetic resonance imaging data analysis methods using Empirical Mode Decomposition to investigate temporal changes in early Parkinson’s disease. Alzheimer’s Dement Transl Res Clin Interv. 2018 Jan 1;4:372–86.

  • Cummings J, Ballard C, Tariot P, Owen R, Foff E, Youakim J, et al. Pimavanserin: Potential Treatment For Dementia-Related Psychosis. J Prev Alzheimer’s Dis. 2018;5(4):253–8.

  • Cummings JL, Atri A, Ballard C, Boneva N, Frolich L, Molinuevo JL. Insights into globalization: comparison of patient characteristics and disease progression among geographic regions in a multinational Alzheimer’s disease clinical program. 2018 Nov.

  • Cummings JL, Cohen S, van Dyck CH, Brody M, Curtis C, Cho W, et al. A phase 3 randomized trial of crenezumab in mild to moderate Alzheimer disease. Neurology. 2018 May 22;90(21):e1889–97.

  • Cummings JL, Fulkerson N. Neurodegeneration research: Advances in clinical translational neuroscience infrastructure and methods. Vol. 4, Alzheimer’s and Dementia: Translational Research and Clinical Interventions. Elsevier Inc; 2018. p. 326–9.

  • Cummings J, Fox N, Vellas B, Aisen P, Shan G, EU/US Alzheimer’s Disease Task Force. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer’s Disease Task Force. J Prev Alzheimer’s Dis. 2018 Mar 16;5:103–9.

  • Cummings J, Lee G, Ritter A, Zhong K. Alzheimer’s disease drug development pipeline: 2018. Alzheimer’s Dement Transl Res Clin Interv. 2018 Jan 1;4:195–214.

  • Cummings J, Reiber C, Kumar P. The price of progress: Funding and financing Alzheimer’s disease drug development. Alzheimer’s Dement Transl Res Clin Interv. 2018 Jan 1;4:330–43.

  • Egan MF, Kost J, Tariot PN, Aisen PS, Cummings JL, Vellas B, et al. Randomized Trial of Verubecestat for Mild-to-Moderate Alzheimer’s Disease. N Engl J Med. 2018 May 3;378(18):1691–703.

  • Finger E, Berry S, Cummings J, Coleman K, Hsiung R, Feldman HH, et al. Adaptive crossover designs for assessment of symptomatic treatments targeting behaviour in neurodegenerative disease: A phase 2 clinical trial of intranasal oxytocin for frontotemporal dementia (FOXY). Alzheimer’s Res Ther. 2018 Sep 27;10(1).

  • Hampel H, Vergallo A, Aguilar LF, Benda N, Broich K, Cuello AC, et al. Precision pharmacology for Alzheimer’s disease. Vol. 130, Pharmacological Research. Academic Press; 2018. p. 331–65.

  • Hilpert JC, Marchand GC. Complex Systems Research in Educational Psychology: Aligning Theory and Method. Educ Psychol. 2018 Jul 3;53(3):185–202.

  • Lee BG, Leavitt MJ, Bernick CB, Leger GC, Rabinovici G, Banks SJ. A Systematic Review of Positron Emission Tomography of Tau, Amyloid Beta, and Neuroinflammation in Chronic Traumatic Encephalopathy: The Evidence To Date. J Neurotrauma. 2018 Sep 1;35(17):2015–24.

  • Liu-Seifert H, Siemers E, Sundell K, Mynderse M, Cummings J, Mohs R, et al. Analysis of the Relationship of Cognitive Impairment and Functional Impairment in Mild Alzheimer’s Disease in EXPEDITION 3. Anal Relatsh Cogn Impair Funct Impair Mild Alzheimer’s Dis Exped 3. 2018 May 29;5(3):184–7.

  • Malek-Ahmadi M, Beach TG, Zamrini E, Adler CH, Sabbagh MN, Shill HA, et al. Faster cognitive decline in dementia due to Alzheimer disease with clinically undiagnosed Lewy body disease. PLoS One. 2018 Mar 1;14(6).

  • Marchand GC, Hilpert JC, Bragg KM, Cummings J. Network-based assessment of collaborative research in neuroscience. Alzheimer’s Dement Transl Res Clin Interv. 2018 Jan 1;4:433–43.

  • Marchand GC, Hilpert JC. Design Considerations for Education Scholars Interested in Complex Systems Research [Internet]. Vol. 15, Complicity. 2018. Available from: https://digitalscholarship.unlv.edu/edpsych_fac_articles https://digitalscholarship.unlv.edu/edpsych_fac_articles/197

  • Miller JB, Cummings J, Nance C, Ritter A. Neuroscience learning from longitudinal cohort studies of Alzheimer’s disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience. Vol. 4, Alzheimer’s and Dementia: Translational Research and Clinical Interventions. Elsevier Inc; 2018. p. 350–6.

  • Miller JB, Shan G, Lombardo J, Jimenez-Maggoria G. Biomedical informatics applications for precision management of neurodegenerative diseases. Alzheimer’s Dement Transl Res Clin Interv. 2018 Jan 1;4:357–65.

  • Mishra V, Sreenivasan K, Banks SJ, Zhuang X, Yang Z, Cordes D, et al. Investigating structural and perfusion deficits due to repeated head trauma in active professional fighters. NeuroImage Clin. 2018;17:616–27.

  • Molinuevo JL, Ayton S, Batrla R, Bednar MM, Bittner T, Cummings J, et al. Current state of Alzheimer’s fluid biomarkers. Acta Neuropathol. 2018 Dec 1;136:821–53.

  • Murtishaw AS, Heaney CF, Bolton MM, Belmonte KCD, Langhardt MA, Kinney JW. Intermittent streptozotocin administration induces behavioral and pathological features relevant to Alzheimer’s disease and vascular dementia. Neuropharmacology. 2018 Jul 15;137:164–77.

  • Sano M, Soto M, Carrillo M, Cummings J, Hendrix S, Mintzer J, et al. Identifying Better Outcome Measures to Improve Treatment of Agitation in Dementia: A Report from the EU/US/CTAD Task Force. J Prev Alzheimer’s Dis. 2018;5(2):98–102.

  • Shan G. Exact confidence limits for the response rate in two-stage designs with over- or under-enrollment in the second stage. Stat Methods Med Res. 2018 Apr 1;27(4):1045–55.

  • Shan G. Exact confidence limits for the probability of response in two-stage designs. Statistics (Ber). 2018 Sep 3;52(5):1086–95.

  • Shan G, Banks S, Miller JB, Ritter A, Bernick C, Lombardo J, et al. Statistical advances in clinical trials and clinical research. Alzheimer’s Dement Transl Res Clin Interv. 2018 Jan 1;4:366–71.

  • Shan G, Bernick C, Banks S. Sample size determination for a matched-pairs study with incomplete data using exact approach. Br J Math Stat Psychol. 2018 Feb 1;71(1):60–74.

  • Shan G, Chen JJ. Optimal inference for Simon’s two-stage design with over or under enrollment at the second stage. Commun Stat – Simul Comput. 2018 Jun 20;47(4):1157–67.

  • Shan G, Kang L, Xiao M, Zhang H, Jiang T. Accurate unconditional p-values for a two-arm study with binary endpoints. J Stat Comput Simul. 2018 Jan 28;88(6):1200–10.

  • Shan G, Zhang H, Jiang T. Determining sample size for a binary diagnostic test in the presence of verification bias. J Biopharm Stat. 2018 Mar 19;28(6):1193–202.

  • Sharma S, Young RJ, Chen J, Chen X, Oh EC, Schiller MR. Minimotifs dysfunction is pervasive in neurodegenerative disorders. Alzheimer’s Dement Transl Res Clin Interv. 2018 Jan 1;4:414–32.

  • Taasoobshirazi G, Puckett C, Marchand G. Stereotype Threat and Gender Differences in Biology. Int J Sci Math Educ. 2018 Oct 2;17:1267–82.

  • Torosyan N, Sethanandha C, Grill JD, Dilley ML, Lee J, Cummings JL, et al. Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer’s disease: Results of a randomized, double-blinded, pilot study. Exp Gerontol. 2018 Oct 1;111:118–21.

  • Vergallo A, Bun RS, Toschi N, Baldacci F, Zetterberg H, Blennow K, et al. Association of cerebrospinal fluid α-synuclein with total and phospho-tau181 protein concentrations and brain amyloid load in cognitively normal subjective memory complainers stratified by Alzheimer’s disease biomarkers. Alzheimer’s Dement. 2018 Dec 1;14(12):1623–31.

  • Voss T, Li J, Cummings J, Farlow M, Assaid C, Froman S, et al. Randomized, controlled, proof-of-concept trial of MK-7622 in Alzheimer’s disease. Alzheimer’s Dement Transl Res Clin Interv. 2018 Jan 1;4:173–81.

  • Yang Z, Zhuang X, Sreenivasan K, Mishra V, Curran T, Byrd R, et al. 3D spatially-adaptive canonical correlation analysis: Local and global methods. Neuroimage. 2018 Apr 1;169:240–55.

  • Zhuang X, Walsh RR, Sreenivasan K, Yang Z, Mishra V, Cordes D. Incorporating spatial constraint in co-activation pattern analysis to explore the dynamics of resting-state networks: An application to Parkinson’s disease. Neuroimage. 2018 May 15;172:64–84.

Publications in 2017

  • Abushakra S, Porsteinsson A, Scheltens P, Sadowsky C, Vellas B, Cummings J, et al. CLINICAL EFFECTS OF TRAMIPROSATE IN APOE4/4 HOMOZYGOUS PATIENTS WITH MILD ALZHEIMER’S DISEASE SUGGEST DISEASE MODIFICATION POTENTIAL. Hournal Prev Alzheimer’s Dis. 2017 Jul 22;4(3):149–56.

  • Aisen PS, Cummings J, Jack CR, Morris JC, Sperling R, Frölich L, et al. On the path to 2025: Understanding the Alzheimer’s disease continuum. Vol. 9, Alzheimer’s Research and Therapy. BioMed Central Ltd.; 2017.

  • Atri A, Frölich L, Ballard C, Tariot P, Molinuevo JL, Boneva N, et al. IDALOPIRDINE, A 5-HT6 ANTAGONIST, AS ADJUNCTIVE THERAPY TO ACETYLCHOLINESTERASE INHIBITORS IN PATIENTS WITH MILD-MODERATE ALZHEIMER’s DISEASE: KEY OUTCOMES FROM THE STAR PHASE III PROGRAM. J Alzheimer’s Assoc. 2017 Jul 1;13(7S):1476–7.

  • Banks SJ, Miller JB, Rissman RA, Bernick CB. Lack of Influence of Apolipoprotein E Status on Cognition or Brain Structure in Professional Fighters. J Neurotrauma. 2017 Jan 15;34(2):380–4.

  • Bloniecki V, Aarsland D, Blennow K, Cummings J, Falahati F, Winblad B, et al. Effects of Risperidone and Galantamine Treatment on Alzheimer’s Disease Biomarker Levels in Cerebrospinal Fluid. J Alzheimers Dis. 2017;57(2):387–93.

  • Bluett B, Litvan I, Cheng S, Juncos J, Riley DE, Standaert DG, et al. Understanding falls in progressive supranuclear palsy. Park Relat Disord. 2017 Feb 1;35:75–81.

  • Caldwell JZK, Berg JL, Cummings JL, Banks SJ. Moderating effects of sex on the impact of diagnosis and amyloid positivity on verbal memory and hippocampal volume. Alzheimer’s Res Ther. 2017 Sep 12;9(1).

  • Cordes D, Yang Z, Zhuang X, Sreenivasan K, Mishra V, Hua LH. A new algebraic method for quantitative proton density mapping using multi-channel coil data. Med Image Anal. 2017 Aug 1;40:154–71.

  • Cummings J, Fox N. DEFINING DISEASE MODIFYING THERAPY FOR ALZHEIMER’S DISEASE. J Prev Alzheimer’s Dis. 2017;1–7.

  • Cummings J. Disease modification and Neuroprotection in neurodegenerative disorders. Vol. 6, Translational Neurodegeneration. BioMed Central Ltd.; 2017.

  • Cummings J, Lee G, Mortsdorf T, Ritter A, Zhong K. Alzheimer’s disease drug development pipeline: 2017. Vol. 3, Alzheimer’s and Dementia: Translational Research and Clinical Interventions. Elsevier Inc; 2017. p. 367–84.

  • Cummings J, Scheltens P, Mckeith I, Blesa R, Harrison JE, Bertolucci PHF, et al. Effect size analyses of souvenaid in patients with Alzheimer’s disease. J Alzheimer’s Dis. 2017;55(3):1131–9.

  • Durant J, Berg J-L, Banks SJ, Miller JB. Comparing the test of practical judgment with the neuropsychological assessment battery judgment subtest in a neurodegenerative disease clinic population. Appl Neuropsychol Adult. 2017 Jun 12;25(6):489–96.

  • Ismail Z, Agüera-Ortiz L, Brodaty H, Cieslak A, Cummings J, Fischer CE, et al. The Mild Behavioral Impairment Checklist (MBI-C): A Rating Scale for Neuropsychiatric Symptoms in Pre-Dementia Populations. J Alzheimer’s Dis. 2017;56(3):929–38.

  • LaBelle DR, Lee BG, Miller JB. Dissociation of Executive and Attentional Elements of the Digit Span Task in a Population of Older Adults: A Latent Class Analysis. Assessment. 2017 Jun 16;26(7).

  • Labelle DR, Walsh RR, Banks SJ. Latent Cognitive Phenotypes in de Novo Parkinson’s Disease: A Person-Centered Approach. J Int Neuropsychol Soc. 2017 Aug 1;23(7):551–63.

  • Lee JK, Wu J, Banks S, Bernick C, Massand MG, Modic MT, et al. Prevalence of traumatic findings on routine MRI in a large cohort of professional fighters. Am J Neuroradiol. 2017 Jul 1;38(7):1303–10.

  • Liu X, Shan G, Tian L, Ma C-X. Exact methods for testing homogeneity of proportions for multiple groups of paired binary data. Commun Stat – Simul Comput. 2017 Mar 21;46(8):6074–82.

  • Mishra VR, Zhuang X, Sreenivasan KR, Banks SJ, Yang Z, Bernick C, et al. Multimodal MR imaging signatures of cognitive impairment in active professional fighters. Radiology. 2017 Nov 1;285(2):555–67.

  • Rinne JO, Wesnes K, Cummings JL, Hakulinen P, Hallikainen M, Hänninen J, et al. Tolerability of ORM-12741 and effects on episodic memory in patients with Alzheimer’s disease. Alzheimer’s Dement Transl Res Clin Interv. 2017 Jan 1;3(1):1–9.

  • Ritter AR, Leger GC, Miller JB, Banks SJ. Neuropsychological Testing in Pathologically Verified Alzheimer Disease and Frontotemporal Dementia: How Well Do the Uniform Data Set Measures Differentiate Between Diseases? Alzheimer Dis Assoc Disord. 2017;31(3):187–91.

  • Ritter A, Hawley N, Banks SJ, Miller JB. The Association between Montreal Cognitive Assessment Memory Scores and Hippocampal Volume in a Neurodegenerative Disease Sample. J Alzheimer’s Dis. 2017;58(3):695–9.

  • Shan G, Chen JJ, Ma C. Boundary problem in Simon’s two-stage clinical trial designs. J Biopharm Stat. 2017 Jan 2;27(1):25–33.

  • Shan G, Gerstenberger S. Fisher’s exact approach for post hoc analysis of a chi-squared test. PLoS One. 2017 Dec 1;12(12).

  • Shan G, Zhang H, Jiang T. Efficient confidence limits for adaptive one-arm two-stage clinical trials with binary endpoints. BMC Med Res Methodol. 2017 Feb 6;17(1):1–11.

  • Sreenivasan K, Zhuang X, Banks SJ, Mishra V, Zhengshi Y, Gopikrishna D, et al. Olfactory Network Differences in Master Sommeliers: Connectivity Analysis Using Granger Causality and Graph Theoretical Approach. Brain Connect. 2017 Mar 1;7(2):123–36.

  • Whittaker A, Smith KP, Shan G. Pharmacy residency school-wide match rates and modifiable predictors in ACPE-accredited colleges and schools of pharmacy. Am J Pharm Educ. 2017;81(10):56–63.

  • Xiao M, Jiang T, Zhang H, Shan G. Exact One-Sided Confidence Limit for the Ratio of Two Poisson Rates. Stat Biopharm Res. 2017 May 12;9(2):180–5.

  • Zhang H, Jiang T, Shan G, Xu S, Song Y. Gaussian network model can be enhanced by combining solvent accessibility in proteins. Sci Rep. 2017 Dec 1;7(1).

  • Zhang H, Shan G, Young D. Comparison of unweighted and weighted rank based tests for an ordered alternative in randomized complete block designs. Commun Stat – Simulations Comput. 2017 Jan 25;46(6):4452–64.

  • Zhuang X, Yang Z, Curran T, Byrd R, Nandy R, Cordes D. A family of locally constrained CCA models for detecting activation patterns in fMRI. Neuroimage. 2017 Apr 1;149:63–84.

  • Zink DN, Miller JB, Caldwell JZK, Bird C, Banks SJ. The relationship between neuropsychological tests of visuospatial function and lobar cortical thickness. J Clin Exp Neuropsychol. 2017 Nov 7;40(5):518–27.

Publications in 2016

  • Abushakra S, Porsteinsson A, Vellas B, Cummings J, Gauthier S, Hey JA, et al. CLINICAL BENEFITS OF TRAMIPROSATE IN ALZHEIMER’S DISEASE ARE ASSOCIATED WITH HIGHER NUMBER OF APOE4 ALLELES: THE “APOE4 GENE-DOSE EFFECT.” J Prev Alzheimer’s Dis. 2016 Oct 24;3(4):219–28.

  • Aisen P, Touchon J, Andrieu S, Boada M, Doody R, Nosheny RL, et al. REGISTRIES AND COHORTS TO ACCELERATE EARLY PHASE ALZHEIMER’S TRIALS. A REPORT FROM THE E.U./U.S. CLINICAL TRIALS IN ALZHEIMER’S DISEASE TASK FORCE. J Prev Alzheimer’s Dis. 2016;1–7.

  • Baldock D, Miller JB, Leger GC, Banks SJ. Memory Test Performance on Analogous Verbal and Nonverbal Memory Tests in Patients with Frontotemporal Dementia and Alzheimer’s Disease. Dement Geriatr Cogn Dis Extra. 2016;6(1):20–7.

  • Banks SJ, Sreenivasan KR, Weintraub DM, Baldock D, Noback M, Pierce ME, et al. Structural and functional MRI differences in master sommeliers: A pilot study on expertise n the brain. Front Hum Neurosci. 2016 Aug 22;10:12.

  • Berg J-L, Durant J, Banks SJ, Miller JB. Estimates of premorbid ability in a neurodegenerative disease clinic population: comparing the Test of Premorbid Functioning and the Wide Range Achievement Test, 4th Edition. Clin Neuropsychol. 2016 Apr 29;30(4):547–57.

  • Berg J-L, Swan NM, Banks SJ, Miller JB. Atypical performance patterns on Delis–Kaplan Executive Functioning System Color–Word Interference Test: Cognitive switching and earning ability in older adults. J Clin Exp Neuropsychol. 2016 May 1;38(7):745–51.

  • Cummings J, Aisen P, Barton R, Bork J, Doody R, Dwyer J, et al. RE-ENGINEERING ALZHEIMER CLINICAL TRIALS: GLOBAL ALZHEIMER’S PLATFORM NETWORK. J Prev Alzheimer’s Dis. 2016;1–7.

  • Cummings JL, Zhong K, Kinney JW, Heaney C, Moll-Tudla J, Joshi A, et al. Double-blind, placebo-controlled, proof-of-concept trial of bexarotene Xin moderate Alzheimer’s disease. Alzheimer’s Res Ther. 2016 Jan 29;8(1).

  • Cummings J, Aisen PS, Dubois B, Frölich L, Jack CR, Jones RW, et al. Drug development in Alzheimer’s disease: The path to 2025. Alzheimer’s Res Ther. 2016 Sep 20;8(1).

  • Cummings J, Lai TJ, Hemrungrojn S, Mohandas E, Yun Kim S, Nair G, et al. Role of Donepezil in the Management of Neuropsychiatric Symptoms in Alzheimer’s Disease and Dementia with Lewy Bodies. CNS Neurosci Ther. 2016 Mar 1;22(3):159–66.

  • Cummings J, Morstorf T, Lee G. Alzheimer’s drug-development pipeline: 2016. Alzheimer’s Dement Transl Res Clin Interv. 2016 Nov 1;2(4):222–32.

  • Dubois B, Hampel H, Feldman HH, Scheltens P, Aisen P, Andrieu S, et al. Preclinical Alzheimer’s disease: Definition, natural history, and diagnostic criteria. Vol. 12, Alzheimer’s and Dementia. Elsevier Inc.; 2016. p. 292–323.

  • Durant J, Leger GC, Banks SJ, Miller JB. Relationship between the Activities of Daily Living Questionnaire and the Montreal Cognitive Assessment. Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2016;4:43–6.

  • Izuora KE, Ezeanolue EE, Neubauer MF, Gewelber CL, Allenback GL, Shan G, et al. Changes in Inflammatory and Bone Turnover Markers After Periodontal Disease Treatment in Patients With Diabetes [Internet]. 2016. Available from: www.amjmedsci.com

  • Jacobs J, Banks S, Zelmann R, Zijlmans M, Jones-Gotman M, Gotman J. Spontaneous ripples in the hippocampus correlate with epileptogenicity and not memory function in patients with refractory epilepsy. Epilepsy Behav. 2016 Sep 1;62:258–66.

  • Kim HJ, Choi KH, Kim SH, Cummings JL, Yang DW. Validation Study of the Korean Version of the Brief Clinical Form of the Neuropsychiatric Inventory. Dement Geriatr Cogn Dis Extra. 2016;6(2):214–21.

  • Liu-Seifert H, Siemers E, Selzler K, Sundell K, Aisen P, Cummings J, et al. CORRELATION BETWEEN COGNITION AND FUNCTION ACROSS THE SPECTRUM OF ALZHEIMER’S DISEASE. J Prev Alzheimer’s Dis. 2016;1–7.

  • Murtishaw AS, Heaney CF, Bolton MM, Sabbagh JJ, Langhardt MA, Kinney JW. Effect of acute lipopolysaccharide-induced inflammation in intracerebroventricular-streptozotocin injected rats. Neuropharmacology. 2016 Feb 1;101:110–22.

  • Shan G. Exact sample size determination for the ratio of two incidence rates under the Poisson distribution. Comput Stat. 2016 Mar 26;31:1633–44.

  • Shan G. Sample size calculation for agreement between two raters with binary endpoints using exact tests. Stat Methods Med Res. 2016 Nov 16;27(7).

  • Shan G, Wilding GE, Hutson AD, Gerstenberger S. Optimal adaptive two-stage designs for early phase II clinical trials. Stat Med. 2016 Apr 15;35(8):1257–66.

  • Shan G, Zhang H, Jiang T. Minimax and admissible adaptive two-stage designs in phase II clinical trials. BMC Med Res Methodol. 2016 Aug 2;16(1).

  • Shan G, Zhang H, Jiang T, Peterson H, Young D, Ma C. Exact p-Values for Simon’s Two-Stage Designs in Clinical Trials. Stat Biosci. 2016 Oct 1;8(2):351–7.

  • Shen JJ, Cochran CR, Mazurenko O, Moseley CB, Shan G, Mukalian R, et al. Racial and insurance status disparities in patient safety indicators among hospitalized patients. Ethn Dis. 2016 Jun 1;26(3):443–52.

  • Sunny CE, Taasoobshirazi G, Clark L, Marchand G. Stereotype threat and gender differences in chemistry. Instr Sci. 2016 Sep 8;45(2):157–75.

  • Wang J, Logovinsky V, Hendrix SB, Stanworth SH, Perdomo C, Xu L, et al. ADCOMS: A composite clinical outcome for prodromal Alzheimer’s disease trials. J Neurol Neurosurg Psychiatry. 2016 Sep 1;87(9):993–9.

  • Xu J, Shan G, Amei A, Zhao J, Young D, Clark S. A modified Friedman test for randomized complete block designs. Commun Stat – Simul Comput. 2016 Nov 11;46(2):1508–19.

  • Yuan J, Zhang Z, Wen H, Hong X, Hong Z, Qu Q, et al. Incidence of dementia and subtypes: A cohort study in four regions in China. Alzheimer’s Dement. 2016 Mar 1;12(3):262–71.

  • Zenisek R, Millis SR, Banks SJ, Miller JB. Prevalence of below-criterion Reliable Digit Span scores in a clinical sample of older adults. Arch Clin Neuropsychol. 2016 Aug 1;31(5):426–33.

  • Zhang H, Jiang T, Shan G. Identification of hot spots in protein structures using Gaussian network model and Gaussian naive bayes. Biomed Res Int. 2016;2016.

     

Publications in 2015

  • Bonner-Jackson A, Mahmoud S, Miller J, Banks SJ. Verbal and non-verbal memory and hippocampal volumes in a memory clinic population. Alzheimer’s Res Ther. 2015 Oct 15;7(1).

  • Cummings J, Zhong K. Trial design innovations: Clinical trials for treatment of neuropsychiatric symptoms in Alzheimer’s Disease. Clin Pharmacol Ther. 2015 Nov 1;98(5):483–5.

  • Cummings JL, Lyketsos CG, Peskind ER, Porsteinsson AP, Mintzer JE, Scharre DW, et al. Effect of dextromethorphan-quinidine on agitation in patients with Alzheimer disease dementia a randomized clinical trial. JAMA – J Am Med Assoc. 2015 Sep 22;314(12):1242–54.

  • Ghazi-Saidi L, Walsh RR, Shan G, Banks SJ. Biomarkers of Cognitive Impairment Brain Cortical Thickness, Volumetrics, and Cerebrospinal Fluid [Internet]. Vol. 32, Alzheimer Dis Assoc Disord. Available from: www.alzheimerjournal.com%7C255

  • Grill JD, Raman R, Ernstrom K, Aisen P, Dowsett SA, Chen YF, et al. Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer’s disease clinical trials. Alzheimer’s Res Ther. 2015 Jun 25;7(1).

  • Henley DB, Dowsett SA, Chen YF, Liu-Seifert H, Grill JD, Doody RS, et al. Alzheimer’s disease progression by geographical region in a clinical trial setting. Alzheimer’s Res Ther. 2015 Jun 25;7(1).

  • Mao HF, Kuo CA, Huang WN, Cummings JL, Hwang TJ. Values of the minimal clinically important difference for the neuropsychiatric inventory questionnaire in individuals with dementia. J Am Geriatr Soc. 2015 Jul 1;63(7):1448–52.

  • Masters CL, Bateman R, Blennow K, Rowe CC, Sperling RA, Cummings JL. Alzheimer’s disease. Vol. 1, Nature Reviews Disease Primers. Nature Publishing Group; 2015.

  • Mazurenko O, Gupte G, Shan G. Analyzing U.S. nurse turnover: Are nurses leaving their jobs or the profession itself? J Hosp Adm. 2015 May 13;4(4).

  • Pakhomov SVS, Marino SE, Banks S, Bernick C. Using automatic speech recognition to assess spoken responses to cognitive tests of semantic verbal fluency. Speech Commun. 2015 Dec 1;75:14–26.

  • Ritter A, Cummings J. Fluid biomarkers in clinical trials of Alzheimer’s disease therapeutics. Vol. 6, Frontiers in Neurology. Frontiers Media S.A.; 2015.

  • Shan G. Exact confidence intervals for randomized response strategies. J Appl Stat. 2015 Mar 12;43(7):1279–90.

  • Shan G. Improved confidence intervals for the Youden Index. PLoS One. 2015 Jul 1;10(7).

  • Shan G, Amei A, Young D. Efficient noninferiority testing procedures for simultaneously assessing sensitivity and specificity of two diagnostic tests. Comput Math Methods Med. 2015;2015.

  • Soto M, Abushakra S, Cummings J, Siffert J, Robert P, Vellas B, et al. PROGRESS IN TREATMENT DEVELOPMENT FOR NEUROPSYCHIATRIC SYMPTOMS IN ALZHEIMER’S DISEASE: FOCUS ON AGITATION AND AGGRESSION. A REPORT FROM THE EU/US/CTAD TASK FORCE. J Prev Alzheimer’s Dis. 2015;1–6.

  • Vogel SJ, Banks SJ, Cummings JL, Miller JB. Concordance of the Montreal cognitive assessment with standard neuropsychological measures. Alzheimer’s Dement Diagnosis, Assess Dis Monit. 2015 Sep 1;1(3):289–94.

  • Wang W, Shan G. Exact confidence intervals for the relative risk and the odds ratio. Biometrics. 2015 Dec 1;71(4):985–95.

  • Wessels AM, Siemers ER, Yu P, Andersen SW, Holdridge KC, Sims JR, et al. A COMBINED MEASURE OF COGNITION AND FUNCTION FOR CLINICAL TRIALS: THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS). J Prev Alzheimer’s Dis. 2015;1–15.